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ABSTR ACT: Highly active antiretroviral (ARV) therapy (HAART) for chronic suppression of HIV replication has revolutionized the treatment of HIV/
AIDS. HAART is no panacea; treatments must be maintained for life. Although great progress has been made in ARV therapy, HIV continues to replicate
in anatomical and intracellular sites where ARV drugs have restricted access. Nanotechnology has been considered a platform to circumvent some of the
challenges in HIV/AIDS treatment. Dispersion polymerization was used to fabricate two types (PMM and ECA) of polymeric nanoparticles, and each
was successfully loaded with four ARV drugs (zidovudine, lamivudine, nevirapine, and raltegravir), followed by physicochemical characterization: scanning
electron microscope, particle size, zeta potential, drug loading, and in vitro availability. These nanoparticles efficiently inhibited HIV-1 infection in CEM
T cells and peripheral blood mononuclear cells; they hold promise for the treatment of HIV/AIDS. The ARV-loaded nanoparticles with polyethylene glycol
on the corona may facilitate tethering ligands for targeting specific receptors expressed on the cells of HIV reservoirs.
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Introduction

Highly active antiretroviral (ARV) therapy (HAART)
for chronic suppression of HIV replication has revolutionized the treatment of HIV/AIDS: many patients are now
in their second decade of treatment, with levels of plasma
HIV RNA below the limits of detection of clinical assays.1
However, HAART is no panacea. Current treatments
must be maintained for life. Although great progress has
been made in ARV therapy, HIV continues to replicate in
anatomical and intracellular sites where ARV drugs have
restricted access. 2 Thus, there is a great need for continued
efforts in seeking innovative approaches for the treatment
of HIV/AIDS. Cellular and anatomical reservoirs of HIV-1
represent major impediments to eradication. 3 Cellular reservoirs include latently infected CD4+ T cells, macrophages, and follicular dendritic cells. The main anatomical
reservoir sites for HIV include the lymphoid organs (particularly the gut-associated lymphoid tissue [GALT]) and
the brain. 3 They are the sites of persistent HIV replication.
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HIV is active in the GALT throughout the period of clinical latency, although minimal viral burden is observed in
the blood.4–6
Viral replication occurs predominantly in the peripheral lymphoid organs, and the GALT is an important site of
active viral replication, possibly reflecting high levels of T-cell
activation.3,7–10 The maintenance of viral reservoirs revolves
around the GALT of HIV-infected individuals despite longterm viral suppression.2,11 The belief is that the ongoing low
level of replication in the GALT may replenish the cellular
reservoir.12 Given the restricted access of HAART to anatomical reservoirs, nanotechnology has been considered
a platform that can be brought to bear to circumvent some
of the challenges in HIV/AIDS treatment. Nanomedicine
platforms that deliver ARV agents to HIV reservoirs (drug
polymer conjugates, dendrimers, micelles, liposomes, solid
nanoparticles, nanosuspensions, polymeric nanoparticles, and
cell-mediated nanoparticles) have been discussed recently.2
Polymeric nanoparticles have higher drug-loading capacity
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Scheme 1. Surface-modified nanoparticles capable of crossing the intestinal epithelium via β1-integrin receptors on M cells.

and the potential to target HIV reservoirs by manipulation of
their surface characteristics.13–15 Polymeric nanoparticles are
preferentially taken up by the M cells of Peyer’s patches of the
GALT.16 Although M cells possess the capability to transcytose synthetic nanoparticles, the absorption occurs at very
low levels. Thus, there is scope for the application of the concept of site-specific targeting of ARV drug-loaded nanoparticles to M cells to enhance the efficacy of orally administered
ARV drugs.
We believe that grafting an M-cell-targeting ligand to
the nanoparticle surface could improve M-cell oral delivery
strategies by influencing the endocytic mechanisms involved
in their uptake by M cells.17–22 Given the report that the
ongoing low level of replication in the GALT may replenish the latent reservoir,6,12 this series of projects will result
in targeted ARV drugs-loaded nanoparticle delivery system
to facilitate uptake and transcellular transport of the ARV
drugs to minimize GALT reservoir responsible for the
persistent ongoing replication of HIV-1 (ie, adapting drug
delivery system properties to cell requirements), as shown
in Scheme 1. We have used dispersion polymerization (in
situ polymerization) technique previously for the fabrication of nanoparticles for the delivery of bioactive agents. 23–26
In situ polymerization of monomers, including cross-linkers
in the fabrication of polymeric nanoparticles, allows one-pot
synthesis of nanoparticles with many advantages. 26 All the
advantages of in situ polymerization derive from the possibility of simultaneous encapsulation of bioactive agents during
polymerization and, by copolymerization, the possibility of
adding surface functionalities in one-batch process without
further modifications compared to nanoparticle fabrication by dispersion of preformed polymers. 23–27 Our in situ
polymerization technique involves the use of a macromonomer or a monomer that forms the core of the nanoparticles,
a cross-linker that cross-links the core, a redox initiator system, and a hydrophilic macromonomer (polyethylene glycol
[PEG]), which confers the stealth property to the nanoparticles and which also serves as a stabilizer. We have developed polymerizable macromonomers bearing a site-specific
22
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ligand (GRGDS peptide) for the receptor expressed uniquely
on the apical surface of M cells (cell surface β1 integrin) using
low molecular weight (M W ) polydisperse polyethylene glycol
methacrylates MAv = 400 (n = 7) and 2000 (n = 44; MAPEGs) capable of forming nanoparticles with a hydrophobic
core and a hydrophilic crown or corona exposed to the aqueous medium. 28
Here, we fabricated polymeric nanoparticles that were
loaded with four different ARV drugs: zidovudine (nucleoside reverse transcriptase inhibitor), lamivudine (nucleoside
reverse transcriptase inhibitor), nevirapine (nonnucleoside
reverse transcriptase inhibitor), and raltegravir (HIV integrase
strand transfer inhibitor). We tested encapsulation efficiency
and release of ARV drugs and the effect of ARV drugs-loaded
nanoparticles on T cells and macrophages during one-round
HIV-1 infection.

Materials and Methods

Materials. Zidovudine, lamivudine, and nevirapine
(Sigma-Aldrich), raltegravir (APAC Pharmaceutical, LLC),
hydroxylamine hydrochloride (99%; Sigma-Aldrich), pyridine (99+%; Sigma-Aldrich), diethyl ether (99.8%; SigmaAldrich), ethyl alcohol (denatured; Sigma-Aldrich), methyl
alcohol (99.93%; Sigma-Aldrich), acetonitrile (99.93+%;
Sigma-Aldrich), and hydrochloric acid (37%; Fisher
Scientific) were used as received. Methacryloyl chloride (97%;
Sigma-Aldrich) and methyl methacrylate (99%; SigmaAldrich) were vacuum distilled prior to use. Poly(ethylene
glycol)n monomethyl ether monomethacrylate (PEG-MA;
n = 1000; Polysciences Inc.), benzoyl peroxide (BP; 97%;
Sigma-Aldrich), and N-phenyldiethanolamine (NPDEA;
97%; Sigma-Aldrich) were also used without further purification. ε-Caprolactone (Acros) was dried over molecular sieves
(5 Å) for 48 hours and distilled under negative pressure before
use. 2-Hydroxyethyl methacrylate (HEMA; 97%; SigmaAldrich) was dried over molecular sieves (4 Å) for 24 hours
and distilled under negative pressure before use. Toluene (99%;
Acros) and pyridine (99%; Sigma-Aldrich) were refluxed
over calcium hydride for one hour and distilled prior to use.

Antiretroviral drugs-loaded nanoparticles for HIV/AIDS treatment

Stannous octoate (SnOct; 95%; Sigma-Aldrich) was used as
received. Phosphorus pentoxide (97%; Sigma-Aldrich) was
also used as received.
Cells and media. CD4+ T cells (CEM) were obtained
from the NIH AIDS Research and Reference Reagent
Program. Peripheral blood mononuclear cells (PBMCs) were
purchased from Astra Biologics. Cells were cultured at 37°C
in a 5% CO2 atmosphere in RPMI 1640 medium (Invitrogen)
containing 10% fetal bovine serum and 1% antibiotic solution
(penicillin and streptomycin; Invitrogen). PBMCs were stimulated with 2.5 mg/mL phytohemagglutinin for 24 hours and
then activated for another 24 hours with 10 units/mL interleukin 2 before the infection with vesicular stomatitis virus
g-glycoprotein (VSVg)-pseudotyped HIV-1 virus expressing
luciferase (HIV-1 Luc).
Methods.
Synthesis of hydrolyzable cross-linker (N,O-dimethylacryloylhydroxylamine). The cross-linker, N,O-dimethacryloylhydroxylamine, was synthesized in our laboratory, as described
previously in the literature.23–26,29,30 It involved simultaneous N,O-acylation of hydroxylamine; it was characterized by
proton nuclear magnetic resonance (1H NMR) analysis and
melting point determination.
Synthesis and characterization of methacrylate-terminated
poly-ε-caprolactone macromonomer. The synthesis was done
as reported previously. 26 ε-Caprolactone (13.14 g), HEMA
(4.0 g), and SnOct (three drops) were placed in a 50-mL
round-bottom flask equipped with a magnetic stir bar. The
reaction was kept under vacuum for 10 minutes, and polymerization was carried out in an inert atmosphere by flushing
the flask with nitrogen gas for 24 hours on a silicone oil bath

kept at 128°C. The resulting macromonomer was dissolved in
dichloromethane and filtered. The macromonomer was precipitated out of this solution using an excess amount of hexane and dry ice. Then, the material was filtered and dried in
a vacuum oven at room temperature under reduced pressure
over phosphorus pentoxide for 24 hours. The FT-IR and 1H
NMR spectra of the synthesized macromonomer were consistent with the expected structure. 26,31,32 The number average
M W (Mn) was determined by 1H NMR and gel permeation
chromatography (GPC), while the weight average M W and
polydispersity index of the macromonomer were determined
by GPC using a Waters 2690 GPC system equipped with
a Waters 2410 differential refractive index detector. 24–26
Polystyrene standards were used for calibration and tetrahydrofuran was used as the mobile phase.
Synthesis of nanoparticles.
Methyl methacrylate-based nanoparticles (polymethyl methacrylate [PMM], Scheme 2). 8 mmol of methyl methacrylate,
0.1 mmol of PEG–methyl methacrylate (PEG-MMA)
macromonomer, and 0.162 mmol of the cross-linker (N,Odimethacryloylhydroxylamine) were dissolved in a binary solvent system ethanol:water (10 mL). Ten milligrams of each
of the drugs (zidovudine, lamivudine, nevirapine, and raltegravir) were added. Then, the components of the redox initiator system (0.021 mmol of NPDEA and 0.021 mmol BP)
were injected into the reaction mixture at 10 minutes and
20 minutes, respectively, through a rubber closure under
continuous flushing with nitrogen gas and with continuous
stirring. The overall polymerization time was 24 hours. After
the polymerization, the resulting product was recovered by
centrifugation and lyophilized.
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Scheme 2. Synthesis and structure of stealth hydrolyzable crosslinked PEG-PMMA (PMM) nanoparticles (A = N,O-dimethacryloylhydroxylamine (crosslinker);
B = methyl methacrylate (MMA); C = poly(ethylene glycol)n monomethyl ether monomethacrylate (PEG-MA; n = 1000); D = crosslinked polymer).
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ε-Caprolactone-based nanoparticles (ECA; Scheme 3).
0.24 mmol of poly-caprolactone-HEMA macromonomer
and 0.5 mmol of PEG-MMA, with 0.0209 mmol of crosslinker, were dispersed in acetone:water (10 mL). 0.3325 mmol
of BP and 0.3325 mmol of NDPEA (as co-initiators) were
injected through the rubber closure under continuous flushing
with nitrogen gas and with continuous stirring at 400 rpm.
Ten milligrams of each of the drugs (zidovudine, lamivudine,
nevirapine, and raltegravir) were added. The overall polymerization time was 24 hours. The nanoparticles were recovered
by centrifugation and then lyophilized.
Characterization of the nanoparticles.
Surface morphology. The morphology of the nanoparticles was investigated using scanning electron microscope

(SEM; JSM-5300 SEM; JEOL). The freeze-dried particles
were fixed on a double-sided sticky carbon tape. Then, they
were sputter coated with gold in a Denton Vacuum Inc. Desk II
instrument (45 mA) and examined in the JSM-5300 SEM
instrument at 15 kV.
Particle size analysis and zeta potential. Particle size and size
distribution and zeta potential measurements of the nanoparticles were performed by photon correlation spectroscopy using
Zetasizer® 3000 (Malvern Instruments). The measurement was
performed at 25°C. The dried nanoparticles were suspended in
filtered distilled water (3 mL) by vortexing for one minute on a
touch mixer (Model 231; Fisher Scientific) and then sonicated
for three minutes using a Sonics Vibracell™ Amplitude sonicator (Sonics & Materials, Inc.) before measurement.

Scheme 3. Synthesis and structure of stealth crosslinked poly-ε-Caprolactone-HEMA Nanoparticle (ECA).
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Drug loading and in vitro drug availability.
Preparation of calibration curves for zidovudine, lamivudine, nevirapine, and raltegravir. Hewlett Packard 1100 Series,
a high-performance liquid chromatography (HPLC) system,
was used. Separation was done at 35°C on Eclipse Plus C18
column (4.6 mm × 150 mm) from Agilent Technologies. The
mobile phase comprised solution A (0.01 M KH 2PO4) and B
(acetonitrile). The injection volume was 20 µL. The analysis
was done at gradient mode with a flow rate of 1 mL/minute;
the ratio A/B changed from 90/10 to 20/80 gradually in five
minutes and readily reequilibrated to 90/10. Total analysis time was eight minutes. The stock solution of raltegravir,
nevirapine, zidovudine, and lamivudine (1 mg/mL) was prepared by dissolving 5 mg of each drug in 5 mL of methanol.
Then, the stock solution was diluted with phosphate-buffered
saline (PBS) for the preparation of the working solutions as
follows: 0.025, 0.05, 0.1, 0.25, 0.5, 1.0, 2.5, 5.0, 10.0, 25.0,
50.0, and 100.0 µg/mL. Ultraviolet–visible detection was performed using an HP photodiode array detector. Blank samples showed no interfering substances eluting at the retention
time of raltegravir (retention time, 5.7 minutes; detected at
310 nm), nevirapine (retention time, 4.6 minutes; detected at
285 nm), lamivudine (retention time, 2.7 minutes; detected
at 267 nm), and zidovudine (retention time, 3.7 minutes;
detected at 267 nm). Furthermore, linear calibration curves
(peak areas versus drug concentrations) were established for
raltegravir, nevirapine, zidovudine, and lamivudine over
0.05–100.0 µg/mL concentration range (r 2  0.999).
In vitro availability studies. Drugs (raltegravir, nevirapine, zidovudine, and lamivudine)-loaded nanoparticles
(known weight) were suspended in PBS (pH 7.4; IS 0.16),
placed in a dialysis bag (membrane tubing with MW cutoff of 12,000–14,000) in centrifuge tubes containing known
volume of PBS (pH 7.4; IS 0.16), and rotated at 360°
using Labquake Shaker maintained at 37°C as reported
previously. 23–26 At specific time intervals, an aliquot of the
release medium was taken and replaced with a fresh medium
(maintained at 37°C) each time to keep the volume constant.
Then, the aliquot release medium was filtered through a
0.45-μm syringe filter, and the amount of drugs (raltegravir, nevirapine, zidovudine, and lamivudine) released into
the medium was quantified using a validated HPLC method
(quantitation was carried out according to the standard
curves prepared for the drugs).
Determination of drugs-loading capacity of the nanoparticles.
The determination was done as reported previously.26 The
HPLC analysis was the same as used for the in vitro availability studies of the drugs-loaded nanoparticles described
earlier. The nanoparticles (ANP) were incubated in the release
medium for more than 35 days till all the loaded drugs were
released (each sample in triplicate). Then, quantitation of each
drug (raltegravir, nevirapine, zidovudine, and lamivudine) was
carried out using the standard curves. Encapsulation property
of the nanoparticles was expressed as the loading capacity

(amount of drug encapsulated expressed as a percentage of the
nanoparticles’ weight), using the following equation:
DL =

(ARV) × 100%
(1)
(ANP)

VSVg-pseudotyped HIV-1 Luc. The 293T cells were cotransfected with HIV-1 proviral vector pNL4-3.Luc.R−E− and
VSVg-expressing vector (both obtained from the NIH AIDS
Research and Reference Reagent Program). At 48–72 hours
post transfection, the media containing HIV-1 virions were
collected, filter-sterilized, and kept frozen. HIV-1 Luc was
added to CEM T cells or PBMCs. After 48 hours, the cells
were washed in PBS and lysed with Steady Lite Luciferase
buffer (PerkinElmer). Light emission was analyzed in Luminoskan (PerkinElmer). To adjust for the cell number, the
samples were counted with trypan blue as described in the
following section.
Cell viability assays. Cells were cultured in 96-well plates
at 37°C and incubated with nanoparticles at the indicated concentrations for 24 hours. Cell viability was determined using
trypan blue-based assay. The cells were supplemented with
0.2% trypan blue, transferred to a plastic disposable counting
chamber, and counted on Cellometer Automatic Cell Counter
(Nexcelom Bioscience).
Quantitative PCR for viral DNA analysis. PBMCs were
infected with HIV-1 Luc and treated with nanoparticles for
six hours. Total DNA was extracted from 4 × 106 cells using
lysis buffer (10 mM Tris-HCl pH 8, 10 mM EDTA, 5 mM
NaCl, and 200 µg/mL proteinase K). The cells were lysed
for 20–30 minutes at room temperature, and proteinase K
was inactivated by heating to 95°C for five minutes. For
the real-time PCR analysis, 100 ng DNA was amplified in
Roche LightCycler 480 II (Roche Diagnostics) and SYBR
Green Master mix (Roche Diagnostics). PCR was carried out
with initial preincubation for five minutes at 45°C and then
for three minutes at 95°C followed by 45 cycles of denaturation at 95°C for 15 seconds, annealing and extension at 60°C
for 45 seconds, and final extension at 72°C for 10 seconds.
Quantification of an early LTR was carried out using β-globin
DNA as a normalization standard. Primer sequences for early
LTR were forward-GGCTAACTAGGGAACCCACTG
and reverse-CTGCTAGAGATTTTCCACACTGAC and
for β-globin were forward-CAACCTCAAACAGACACCATGG and reverse-TCCACGTTCACCTTGCCC (for
primer information).33 Mean Cp values for early LTR and
β-globin were determined, and AACT method was used to
calculate the relative expression levels. Unpaired t-test was
used to test for statistical significance.

Results and Discussion

The data obtained from the synthesis of the cross-linker (N,Odimethacryloylhydroxylamine) [m.p.: 55–56°C; 1H NMR
(400 MHz, CDCl3): (C8H11NO3) δ = 2.04 (s, 3H), 2.08
Infectious Diseases: Research and Treatment 2016:9
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(s, 3H) 5.54, 5.8 (s, 2H), 5.9, 6.38 (s, 2H), 9.25 (s, 1H)]
were in agreement with previously obtained data in the literature and in our laboratory.23–26,29,30 Controlled hydrolysis of
the cross-linker in the core of the nanoparticles will facilitate
controlled release of the encapsulated ARV drugs. FT-IR and
1
H NMR spectra of the poly(ε-caprolactone) macromonomer,
the average Mn determined by 1H NMR, and the average M W
determined by GPC together with the polydispersity index
are consistent with the expected structure.26,31,32 The polycaprolactone macromonomer was employed in the dispersion polymerization for the fabrication of ARV drugs-loaded
nanoparticles (ECA nanoparticles).
Two types of nanoparticles were synthesized using dispersion polymerization technique: stealth methyl methacrylatebased (PMM; Scheme 2) and stealth ε-caprolactone-based
(ECA; Scheme 3) nanoparticles. Methyl methacrylate monomer
(Scheme 2) or poly-ε-caprolactone macromonomer (Scheme 3),
PEG-MA (n = 1,000), N,O-dimethacryloylhydroxylamine as
the cross-linking agent, and BP/NPDEA (BP/NPDEA as
redox initiator system) were used for in situ nanoparticle synthesis by free radical dispersion polymerization. PEG macromonomer was used both as a co-monomer and a steric stabilizer
and it formed the corona of the nanoparticles.

Morphological evaluation of the nanoparticles.
Nanoparticle fabrication by dispersion polymerization
was confirmed by SEM for the two types of nanoparticles
(stealth methyl methacrylate based [Scheme 2] and stealth
ε-caprolactone based [Scheme 3]). Scanning electron micrographs of ARV drugs-loaded hydrolyzable cross-linked PEG–
poly-ε-caprolactone nanoparticles (Fig. 1A and 1B) and ARV
drugs-loaded hydrolyzable cross-linked PEG–polymethyl
methacrylate nanoparticles (Fig. 1C) show the formation of
smooth spherical nanoparticles.
The average particle size for cross-linked PEG–
polycaprolactone nanoparticles (Fig. 2A) is 321 ± 36 nm
with 0.344 ± 0.023 PDInanoparticle, while the average particle
size for cross-linked PEG-PMM nanoparticles (Fig. 2B) is
137.9 ± 1.3 nm with 0.280 ± 0.0.021 PDInanoparticle. Thus, the
nanoparticles obtained with poly-ε-caprolactone as the hydrophobic core are bigger than the nanoparticles obtained with
PMM as the hydrophobic core. The particle size distribution is
given by the PDInanoparticle (a PDInanoparticle value of 0.1 indicates
a homogenous monodisperse formulation, while a PDInanoparticle
of 0.3 indicates polydispersity with large variations in particle
size).24 The PDInanoparticle values obtained in this work indicate
that PEG-PMM nanoparticles are more homogenous than

Figure 1. Scanning electron micrographs of ARV drugs-loaded hydrolyzable crosslinked PEG-poly caprolactone (ECA) nanoparticles (A and B) and ARV
drugs-loaded hydrolyzable crosslinked PEG-poly methylmethacrylate (PMM) nanoparticles (C).
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Figure 2. Typical particle size distribution for PEG-polycarpolactone (A) and PEG-polymethymethacrylate (B). ARV drugs-loaded hydrolyzable
crosslinked nanoparticles.

Drug-loading capacity and in vitro availability of
ARV drugs from nanoparticles. Drug-loading capacity
was determined by a validated HPLC method as described
previously and found to be 6.44 ± 0.13% w/w (raltegravir),
2.13 ± 0.25% w/w (lamivudine), 0.88 ± 0.16% w/w
(zidovudine), and 4.15 ± 0.39% w/w (nevirapine) for PEGPMM-based nanoparticles. For PEG–polycaprolactone-based
nanoparticles, the results are as follows: 6.79 ± 0.8% w/w
(raltegravir), 1.02 ± 0.12% w/w (lamivudine), 2.11 ± 0.38%
w/w (zidovudine), and 5.13 ± 0.58% w/w (nevirapine).
While the drug-loading capacity values for each of the drug
are better than the values obtained for paclitaxel loaded
in PEG–poly(L-lactide)25 and docetaxel loaded in PEG–
poly(ε-caprolactone) nanoparticles26 (prepared by dispersion
polymerization), which are 0.25% and 0.8%, respectively, effort
will be made to improve the loading capacity.

PEG–poly-ε-caprolactone nanoparticles. The zeta potential
on the surface of PEG–polycaprolactone-based nanoparticles
is more negative (indicating greater tendency for colloidal stability: −31.4 ± −3.6 mV) than the zeta potential on the surface of PEG-PMM-based nanoparticles (−19.2 ± −2.8 mV).
It has been reported that particle size plays an important role
in determining drug release behavior of drug-loaded nanoparticles and their fate after in vivo administration.34 Furthermore,
the zeta potential results obtained in this work show predominantly negative values. Following administration, nanoparticles
with a positive zeta potential pose a threat of causing transient
embolism and rapid clearance compared to negatively charged
particles. Thus, the pegylated poly-ε-caprolactone-based
nanoparticles and pegylated PMM-based nanoparticles fabricated by dispersion polymerization are very promising: capable
of carrying the drug load to its site of action.35
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Figure 3. Typical particle zeta potential distribution for PEG-polycarpolactone (A) and PEG-polymethymethacrylate (B). ARV drugs-loaded hydrolyzable
crosslinked nanoparticles.
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Figure 4. Cumulative amount released versus time for ARV drugs-loaded PEG-polymethylmethacrylate based nanoparticles (Raltegravir: ε = 8.15–31.28 μg;
Niverapine: ε = 7.5–36.84 μg; Lamivudine: ε = 1.20–3.59 μg; and Zidovudine: ε = 2.06–16.74 μg).

of Amidon and his group,36 whereas the potassium salt of
raltegravir is significantly more soluble in water.37 As shown
in Figures 4 and 5, raltegravir-loaded nanoparticles, with the
highest drug-loading capacity, released the highest amount of
drug, followed by nevirapine (M W: 266.31 g/mol), lamivudine
(M W: 229.26 g/mol), and zidovudine (M W: 267.4 g/mol). Based
on the data from NIH AIDS Research and Reagent Program
(Reagent Information, September 2011), 38 the rank order of
their aqueous solubilities is as follows: nevirapine (0.1 mg/mL:
very slightly insoluble in water)  zidovudine (20 mg/mL:
sparingly soluble)  lamivudine (70 mg/mL: soluble). Thus,
the more hydrophobic ARV drugs have a greater affinity for

Figures 4 and 5 show the in vitro release isotherms
of the ARV drugs from PEG-PMM-based and PEG–
polycaprolactone-based nanoparticles, respectively. The release
is biphasic with an initial rapid release followed by a slower
rate of release. Drug-loading capacity and in vitro availability of the drugs from the nanoparticles appear to be independent of the type of nanoparticles (PEG-PMM-based or
PEG–polycaprolactone-based nanoparticles). It appears that
the physicochemical properties of the drugs control drug
loading and drug release. Raltegravir used in this work (M W:
443.42 g/mol) exhibits poor aqueous solubility (ie, 1 mg/mL);
it is very slightly insoluble according to the classification
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Figure 5. Cumulative amount released versus time for ARV drugs-loaded PEG-polycaprolactone based nanoparticles (Raltegravir: e = 6.31–30.2 μg);
Niverapine: ε = 6.7–57 μg; Lamivudine: ε = 0.14–4.71 μg; and Zidovudine: ε = 0.56–37.46 μg).
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the hydrophobic cores of the nanoparticles; they exhibit high
drug-loading capacity and high drug release.
HIV-1 inhibition experiments. ARV drugs-loaded
stealth PMM-based nanoparticles (containing raltegravir,
lamivudine, zidovudine, and nevirapine) inhibit one-round
HIV-1 infection in cultured T cells and primary PBMCs
(Fig. 6). The ARV-loaded PMM-based nanoparticles inhibited HIV-1 infection in CEM T cells by more than 90% with
low micromolar EC50 (Fig. 6A). We next tested the effect
of the PMM nanoparticles on one-round HIV-1 infection
of PBMCs. The ARV-loaded but not blank nanoparticles
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markedly inhibited HIV-1 replication with EC50 = 14 µM
(Fig. 6B). To confirm that the mechanism of HIV-1 inhibition by the ARV-loaded PMM nanoparticles was due to the
inhibition of HIV-1 reverse transcription (RT), we analyzed
early RT by quantifying HIV-1 DNA.33 The established
HIV-1 inhibitor, zidovudine, inhibited RT (Fig. 6C). The
ARV-loaded PMM nanoparticles (10 μM) inhibited RT,
while blank nanoparticles had little effect (Fig. 6C), suggesting that HIV-1 inhibition was due to the reduction of RT.
To access the toxicity of PMM-based nanoparticles, PBMCs
were treated with different concentrations of PMM-based
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Figure 6. Inhibition of HIV-1 one round infection by PMM nanoparticles. (A) Inhibition of HIV-1 in CEM T cells by ARV combination PMM nanoparticles.
CEM T cells were seeded in 96 wells plates, infected with VSVG HIV-Luc and allowed to incubate overnight. The following day, the cells were treated
with different concentrations of combination anti-retroviral nanoparticles containing lamivudine, zidovudine, nevirapine, and raltegravir. After incubating
overnight, a luciferase activity was measured. The half maximal effective concentration (EC50) was determined with GraphPad Prizm 6 Software.
(B) Inhibition of HIV-1 in peripheral blood mononuclear cells (PBMCs) by ARV combination PMM nanoparticles. Activated PBMCs were seeded in 96
wells plates, infected with VSVG HIV-Luc and allowed to incubate overnight. The following day, the cells were treated with different concentrations of
combination anti-retroviral nanoparticles containing lamivudine, zidovudine, nevirapine, and raltegravir. After incubating overnight, a luciferase activity was
measured. Results were analyzed in Prism. (C) Inhibition of HIV-1 reverse transcriptase (RT) in PBMCs. Activated PBMCs were infected with HIV-1 Luc
and then treated with DMSO, zidovudine, blank PMM nanoparticles or combo (ARV) PMM nanoparticles for 6 hours. DNA was extracted and analyzed by
real-time PCR on Roche 480 II using primers for early HIV-1 LTR and β-globin gene as a reference. The asterisk indicates p = 0.005. Unpaired t-test was
used to determine statistical significance. (D) Effect of ARV combination PMM nanoparticles on PBMCs viability. PBMCs were seeded in 96 well plates,
treated with combination anti-retroviral nanoparticles containing lamivudine, zidovudine, nevirapine, and raltegravir and incubated overnight. Cell viability
was determined with trypan blue exclusion assay. The half maximal cytotoxicity concentration (CC50) was determined with GraphPad Prizm 6 Software.
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nanoparticles and a trypan blue exclusion assay was performed
to assess cell’s viability. The assay showed that the ARV-loaded
PMM-based nanoparticles were toxic at higher concentration
(CC50 = 42 µM; Fig. 6D).
HIV-1 inhibition by ARV drugs-loaded stealth
polycaprolactone (ECA) nanoparticles. We tested ARVloaded ECA nanoparticles for HIV-1 inhibition. In CEM
T cells infected with HIV-1 Luc, the combo (ARV) ECAbased nanoparticles achieved only ~25% inhibition with
EC50 = 0.07 µM (Fig. 7A). This effect was not due to
toxicity as nanoparticles were not toxic at this concentration (CC50 = 0.8 µM; Fig. 7B). Data were not available
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for blank nanoparticles as we could not disperse them well
enough in culture media, possibly due to a low level of PEG
on nanoparticle surface. The ARV-loaded ECA nanoparticles
(10 μM) inhibited HIV-1 RT in the infected PBMCs similar
to zidovudine (Fig. 7C). This was not due to toxicity as the
ARV-loaded PMM-based nanoparticles were toxic at higher
concentrations (CC50 = 25 µM; Fig. 7D).
Taken together, our results indicate that HIV-1 inhibition can be achieved by PMM- and ECA-based nanoparticles
fabricated by dispersion polymerization and loaded with ARV
drugs. As expected, one-round HIV-1 replication was inhibited
at the level of RT. These nanoparticles, fabricated by dispersion
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Figure 7. Inhibition of HIV-1 one round infection by ECA nanoparticles. (A) Inhibition of HIV-1 in CEM T cells by ARV combination ECA nanoparticles.
CEM T cells were seeded in 96 wells plates, infected with VSVG HIV-Luc and allowed to incubate overnight. The following day, the cells were treated
with different concentrations of combination anti-retroviral nanoparticles containing lamivudine, zidovudine, nevirapine, and raltegravir. After incubating
overnight, a luciferase activity was measured. EC50 was determined in GraphPad Prizm 6. (B) Effect of ARV combination ECA nanoparticles on cell
viability in CEM cells. CEM cells were seeded in 96 well plates, treated with combo (ARV) ECA nanoparticles for 6 hours and incubated overnight. Cell
viability was determined with trypan blue exclusion assay. CC50 was determined with GraphPad Prizm 6 Software. (C) Inhibition of HIV-1 RT in PBMCs
by ECA nanoparticles. Activated PBMCs were infected with HIV-1 Luc and treated with combo (ARV) ECA nanoparticles or zidovudine for 6 hours or
left untreated. DNA was extracted and analyzed by real-time PCR on Roche 480 II using primers for early HIV-1 LTR and β-globin gene as a reference.
The asterisk indicates p = 0.01. Unpaired t-test was used to determine statistical significance. (D) Effect of ARV combination ECA nanoparticles on cell
viability in PBMCs. PBMCs were seeded in 96 well plates and treated with combo (ARV) ECA nanoparticles for 6 hours and then incubated overnight.
Cell viability was determined with trypan blue exclusion assay. CC50 was determined with GraphPad Prizm 6 Software.
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polymerization, are very promising, as shown in our current
data and as exemplified by our recent report on the nanoparticle packaging of HIV-1-activating small molecule, SMAPP1,
which was not stable in mouse serum; its activity was preserved
and the stability was improved when encapsulated in similar
nanoparticles.39 We also have preliminary data showing successful nanoparticle packaging of HIV-1 transcription inhibitor, 1E7-03 (Nekhai and Akala, unpublished observation).

Conclusion

We show here that four different ARV drugs (zidovudine
[nucleoside reverse transcriptase inhibitor], lamivudine
[nucleoside reverse transcriptase inhibitor], nevirapine [nonnucleoside reverse transcriptase inhibitor], and raltegravir
[HIV integrase strand transfer inhibitor]) could be loaded
into nanoparticles by dispersion polymerization and released
in vitro. Furthermore, we show here that PMM and ECA
nanoparticles loaded with the four antiretroviral drugs efficiently inhibited HIV-1 infection in CEM T cells and PBMCs.
As expected, ARV-loaded nanoparticles inhibited HIV-1 RT.
The ARV-loaded nanoparticles may help to improve the efficacy of ARV drugs. The ARV-loaded nanoparticles with PEG
on the corona may facilitate tethering ligands for targeting
specific receptors expressed on the cells of HIV reservoirs.
Other advantages of the nanoparticles reported here are as follows: the fabrication of the nanoparticles is a one-pot process
(simultaneous encapsulation of ARV drugs during polymerization) carried out at ambient temperature; it is possible to
add surface functionalities in one-batch process without further modifications compared to nanoparticle fabrication by
dispersion of preformed polymers; the process is surfactant
free; and the ARV drugs combination is typical of clinical
recommendations. We are optimizing these nanoparticles to
target them to the gut and the brain. In conclusion, the ARVloaded nanoparticles will be useful for future ARV therapy.
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